Аннотация:INTRODUCTION:Pregabalin is eliminated primarily via renal excretion.It is reported that even with dose adjustment for renal function, patients with impaired renal function have a high incidence of adverse events.As clinical pharmacist, we have been contributed to the prevention of pregabalin adverse events.We report on the incidence of pregabalin adverse events.METHODS: This retrospective study involved 179 patients who received pregabalin from 2014 to 2015 in Kouseikai Hospital, Japan.We investigated the dosage, age, combined use of opioids, and incidence of adverse events according to chronic kidney disease (CKD) G stage.RESULTS: Eleven patients were taking pregabalin above the recommended dose, 3 of whom experienced adverse events.Adverse events occurred in 3 of 11(27%) patients taking pregabalin above the recommended dose.The other 168 patients were prescribed pregabalin below the manufacturer's recommended dose.Of these 168 patients, 23 patients experienced adverse events, as follows (number of adverse events/ patients in each CKD G stage): G1 (2/28), G2 (8/81), G3a (4/27), G3b (3/15), G4 (1/2), and G5 (5/15).Adverse events occurred in 10 of 109 (9.2%) patients with nonimpaired renal function (stages G1 and G2) and 13 of 59 (22%) patients with impaired renal function (stages G3-G5).Renally impaired patients thus had a significantly higher incidence of adverse events (p=0.020).The average age of patients with adverse events was significantly higher as follows: 72.7613.2 and without adverse events was 65.3613.2(p=0.02) .10 of 168 patients used opioids in combination, and adverse events occurred in 4 of 10 patients .CONCLUSIONS:
